Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia

The optimal dose of in vivo-administrated alemtuzumab in the allogeneic transplantation setting has not been defined. We report our experience on 37 patients with high-risk diseases, mainly acute leukemia (AML 23, ALL 10 patients), who underwent sibling (49%) or unrelated (51%) PBSCT (35 patients),...

Descripción completa

Detalles Bibliográficos
Autores principales: Spyridonidis, A, Liga, M, Triantafyllou, E, Themeli, M, Marangos, M, Karakantza, M, Zoumbos, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191504/
https://www.ncbi.nlm.nih.gov/pubmed/21170091
http://dx.doi.org/10.1038/bmt.2010.308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191504/
https://www.ncbi.nlm.nih.gov/pubmed/21170091
http://dx.doi.org/10.1038/bmt.2010.308

Ejemplares similares